91 related articles for article (PubMed ID: 11051272)
1. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000.
Kaplan O
Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272
[No Abstract] [Full Text] [Related]
2. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A
Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
[TBL] [Abstract][Full Text] [Related]
3. [Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].
Fuchs AG
Medicina (B Aires); 2008; 68(1):13-22. PubMed ID: 18416315
[TBL] [Abstract][Full Text] [Related]
4. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
[TBL] [Abstract][Full Text] [Related]
5. [Targeting the gene of glucose metabolism for the treatment of advanced gliomas].
Oudard S; Miccoli L; Dutrillaux B; Poupon MF
Bull Cancer; 1998 Jul; 85(7):622-6. PubMed ID: 9752269
[TBL] [Abstract][Full Text] [Related]
6. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
[TBL] [Abstract][Full Text] [Related]
7. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.
Floridi A; Paggi MG; Marcante ML; Silvestrini B; Caputo A; De Martino C
J Natl Cancer Inst; 1981 Mar; 66(3):497-9. PubMed ID: 6937706
[TBL] [Abstract][Full Text] [Related]
8. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine.
Bhutia YD; Babu E; Ganapathy V
Biochem J; 2016 Jun; 473(11):1503-6. PubMed ID: 27234586
[TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells.
Fanciulli M; Bruno T; Castiglione S; Del Carlo C; Paggi MG; Floridi A
Oncol Res; 1993; 5(9):357-62. PubMed ID: 8038456
[TBL] [Abstract][Full Text] [Related]
10. Intracellular P-glycoprotein in multidrug resistant tumor cells.
Arancia G; Molinari A; Calcabrini A; Meschini S; Cianfriglia M
Ital J Anat Embryol; 2001; 106(2 Suppl 1):59-68. PubMed ID: 11729998
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration].
Ma Q; Zhang ZS; Zhang YL; Lai ZS
Ai Zheng; 2002 Aug; 21(8):846-9. PubMed ID: 12478890
[TBL] [Abstract][Full Text] [Related]
12. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P
In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756
[TBL] [Abstract][Full Text] [Related]
13. Correspondence re: A. Kumar et al., cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res., 61: 7552-7555, 2001.
Garattini E; Gianni' M; Terao M
Cancer Res; 2002 Apr; 62(7):2192-3; author reply 2193-4. PubMed ID: 11929843
[No Abstract] [Full Text] [Related]
14. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
15. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Marcucci G; Perrotti D; Caligiuri MA
Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
[No Abstract] [Full Text] [Related]
16. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
17. Effect of lonidamine on human malignant gliomas: biochemical studies.
Paggi MG; Carapella CM; Fanciulli M; Del Carlo C; Giorno S; Zupi G; Silvestrini B; Caputo A; Floridi A
J Neurooncol; 1988 Nov; 6(3):203-9. PubMed ID: 3225640
[TBL] [Abstract][Full Text] [Related]
18. To arrest or not to G(2)-M Cell-cycle arrest : commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002.
DiPaola RS
Clin Cancer Res; 2002 Nov; 8(11):3311-4. PubMed ID: 12429616
[No Abstract] [Full Text] [Related]
19. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity.
Bender FC; Reymond MA; Bron C; Quest AF
Cancer Res; 2000 Oct; 60(20):5870-8. PubMed ID: 11059785
[TBL] [Abstract][Full Text] [Related]
20. Identification of proteins associated to multi-drug resistance in LoVo human colon cancer cells.
Visentin M; Simula MP; Sartor F; Petrucco A; De Re V; Toffoli G
Int J Oncol; 2009 May; 34(5):1281-9. PubMed ID: 19360340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
